DSM Pharmaceutical Products has signed an agreement with DecImmune Therapeutics for the initiation of development activities for DecImmune's lead monoclonal antibody therapeutic designed to reduce tissue damage and improve ventricular function associated with myocardial infarction. Financial terms were not disclosed.
The initial development will be performed at DSM Biologics' Groningen facility in the Netherlands, with the objective of progressing manufacture of clinical trial material to DSM's new facility in Brisbane, Australia.
Karen King, president of DSM Biologics, said “We are delighted to be working with DecImmune on their exciting project. DSM is committed to delivering our clients around the world the highest quality solutions and services.”
"Partnering with DSM for its antibody process development and manufacturing enables DecImmune to move rapidly through late preclinical studies and into clinical development. DSM's experience, capacity, and technical expertise in Groningen and Brisbane meet the full range of DecImmune's manufacturing needs. We look forward to working with one of the world's leading science-based companies as our manufacturing partner," said Christopher K. Mirabelli, Ph.D., president and chief executive officer of DecImmune and managing director at HealthCare Ventures, DecImmune's lead investor.